• 1
    Freeze HH. Genetic disorders of glycan degradation. In: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW, Etzler ME, editors. Essentials of Glycobiology. 2nd edition. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2009. Chapter 41.
  • 2
    Cantz M, Gehler J. The mucopolysaccharidoses: Inborn errors of glycosaminoglycan catabolism. Hum Genet 1976;32:233255.
  • 3
    Bernsen PL, Wevers RA, Gabreels FJ et al. Phenotypic expression in mucopolysaccharidosis VII. J Neurol Neurosurg Psychiatry 1987;50:699703.
  • 4
    Neufeld EF, d'Azzo A. Biosynthesis of normal and mutant beta-hexosaminidases. Adv Genet 2001;44:165171.
  • 5
    Tomatsu S, Montano AM, Dung VC et al. Mutations and polymorphisms in GUSB gene in mucopolysaccharidosis VII (Sly Syndrome). Hum Mutat 2009;30:511519.
  • 6
    Gitzelmann R, Wiesmann UN, Spycher MA et al. Unusually mild course of beta-glucuronidase deficiency in two brothers (mucopolysaccharidosis VII). Helv Paediatr Acta 1978;33:413428.
  • 7
    Beaudet AL, Roufa DJ, Caskey CT. Mutations affecting the structure of hypoxanthine: Guanine phosphoribosyltransferase in cultured Chinese hamster cells. Proc Natl Acad Sci USA 1973;70:320324.
  • 8
    Sly WS, Brot FE, Glaser J et al. Beta-glucuronidase deficiency mucopolysaccharidosis. Birth Defects Orig Artic Ser 1974;10:239245.
  • 9
    Neufeld EF, Cantz MJ. Corrective factors for inborn errors of mucopolysaccharide metabolism. Ann N Y Acad Sci 1971;179:580587.
  • 10
    Vogler C, Birkenmeier EH, Sly WS et al. A murine model of mucopolysaccharidosis VII. Gross and microscopic findings in beta-glucuronidase-deficient mice. Am J Pathol 1990;136:207217.
  • 11
    Sands MS, Vogler CA, Ohlemiller KK et al. Biodistribution, kinetics, and efficacy of highly phosphorylated and non-phosphorylated beta-glucuronidase in the murine model of mucopolysaccharidosis VII. J Biol Chem 2001;276:4316043165.
  • 12
    Kenyon KR. Ocular manifestations and pathology of systemic mucopolysaccharidoses. Birth Defects Orig Artic Ser 1976;12:133153.
  • 13
    Nelson J. Incidence of the mucopolysaccharidoses in Northern Ireland. Hum Genet 1997;101:355358.
  • 14
    Barton NW, Furbish FS, Murray GJ et al. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci USA 1990;87:19131916.
  • 15
    Winkel LP, Van den Hout JM, Kamphoven JH et al. Enzyme replacement therapy in late-onset Pompe's disease: A three-year follow-up. Ann Neurol 2004;55:495502.
  • 16
    Rohrbach M, Clarke JT. Treatment of lysosomal storage disorders: Progress with enzyme replacement therapy. Drugs 2007;67:26972716.
  • 17
    Clarke LA. The mucopolysaccharidoses: A success of molecular medicine. Expert Rev Mol Med 2008;10:e1.
  • 18
    Beck M. Therapy for lysosomal storage disorders. IUBMB Life 2010;62:3340.
  • 19
    Papadia F, Lozupone MS, Gaeta A et al. Long-term enzyme replacement therapy in a severe case of mucopolysaccharidosis type II (Hunter syndrome). Eur Rev Med Pharmacol Sci 2011;15:253258.
  • 20
    Lachmann R. Treatments for lysosomal storage disorders. Biochem Soc Trans 2010;38:14651468.
  • 21
    Vogler C, Sands MS, Levy B et al. Enzyme replacement with recombinant beta-glucuronidase in murine mucopolysaccharidosis type VII: Impact of therapy during the first six weeks of life on subsequent lysosomal storage, growth, and survival. Pediatr Res 1996;39:10501054.
  • 22
    Vogler C, Sands MS, Galvin N et al. Murine mucopolysaccharidosis type VII: The impact of therapies on the clinical course and pathology in a murine model of lysosomal storage disease. J Inherit Metab Dis 1998;21:575586.
  • 23
    Sands MS, Vogler C, Kyle JW et al. Enzyme replacement therapy for murine mucopolysaccharidosis type VII. J Clin Invest 1994;93:23242331.
  • 24
    Tomatsu S, Montano AM, Ohashi A et al. Enzyme replacement therapy in a murine model of Morquio A syndrome. Hum Mol Genet 2008;17:815824.
  • 25
    Al Sawaf S, Mayatepek E, Hoffmann B. Neurological findings in Hunter disease: Pathology and possible therapeutic effects reviewed. J Inherit Metab Dis 2008;31:473480.
  • 26
    Liu H, Zhang J, Liu CY et al. Cell therapy of congenital corneal diseases with umbilical mesenchymal stem cells: Lumican null mice. PLoS One 2010;5:e10707.
  • 27
    Kao WW, Liu CY. Roles of lumican and keratocan on corneal transparency. Glycoconj J 2002;19:275285.
  • 28
    Carlson EC, Liu CY, Chikama T et al. Keratocan, a cornea-specific keratan sulfate proteoglycan, is regulated by lumican. J Biol Chem 2005;280:2554125547.
  • 29
    Kadler KE, Hill A, Canty-Laird EG. Collagen fibrillogenesis: Fibronectin, integrins, and minor collagens as organizers and nucleators. Curr Opin Cell Biol 2008;20:495501.
  • 30
    Chen LD, Hazlett LD. Perlecan in the basement membrane of corneal epithelium serves as a site for P. aeruginosa binding. Curr Eye Res 2000;20:260267.
  • 31
    Stepp MA, Gibson HE, Gala PH et al. Defects in keratinocyte activation during wound healing in the syndecan-1-deficient mouse. J Cell Sci 2002;115:45174531.
  • 32
    Alonso-Fernandez JR, Fidalgo J, Colon C. Neonatal screening for mucopolysaccharidoses by determination of glycosaminoglycans in the eluate of urine-impregnated paper: Preliminary results of an improved DMB-based procedure. J Clin Lab Anal 2010;24:149153.
  • 33
    Rowan DJ, Tomatsu S, Grubb JH et al. Long circulating enzyme replacement therapy rescues bone pathology in mucopolysaccharidosis VII murine model. Mol Genet Metab 2012;107:161172.
  • 34
    Liu H, Zhang J, Liu CY et al. Bone marrow mesenchymal stem cells can differentiate and assume corneal keratocyte phenotype. J Cell Mol Med 2012;16:11141124.
  • 35
    Iso Y, Spees JL, Serrano C et al. Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment. Biochem Biophys Res Commun 2007;354:700706.
  • 36
    Noiseux N, Gnecchi M, Lopez-Ilasaca M et al. Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Mol Ther 2006;14:840850.
  • 37
    da Silva Meirelles L, Caplan AI, Nardi NB. In search of the in vivo identity of mesenchymal stem cells. Stem Cells 2008;26:22872299.
  • 38
    Giordano A, Galderisi U, Marino IR. From the laboratory bench to the patient's bedside: An update on clinical trials with mesenchymal stem cells. J Cell Physiol 2007;211:2735.
  • 39
    Lai RC, Tan SS, Teh BJ et al. Proteolytic potential of the MSC exosome proteome: Implications for an exosome-mediated delivery of therapeutic proteasome. Int J Proteomics 2012;2012:971907.